⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 21, 2024Arthritis & RheumatologyOpen Access

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses

Oliver FitzGerald Dafna D. Gladman Philip J. Mease Christopher T. Ritchlin Josef S Smolen Lu Gao Yanhua Hu Miroslawa Nowak Subhashis Banerjee Ian M. Catlett

View Full Paper

Ask AI

Bookmark

Share

Abstract

Our objective was to evaluate the association of serum biomarkers with baseline psoriatic arthritis (PsA) disease activity, pharmacodynamic effects of deucravacitinib on biomarker levels, and the relationship between biomarkers and clinical responses to deucravacitinib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

FitzGerald et al. (2024) studied this question.

synapsesocial.com/papers/68e69105b6db643587617e54 https://doi.org/10.1002/art.42921

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Improvements in <scp>Patient‐Reported</scp> Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial2024 · 3 citations
2Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 TrialBlinded Clinical Trial · 2026 · 2 citations
3Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials2024 · 5 citations
4Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials2024 · 11 citations
5Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial2024